Best Oncology Companies in Catalonia, Spain
The 36 best Oncology companies in Catalonia, Spain in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: STAT Diagnostica.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Catalonia
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | STAT Diagnostica Provider of a diagnostic platform for molecular diagnostics and immunoassays | $54M | 119 mo ago | — | Jordi Carrera Co-Founder & Managing Director | — | 113 patents Microfluidic cartridges for nucleic acid purification and assay automation | — |
| 2 | Ona Therapeutics Provider of therapeutics solution for metastatic cancer | $35M | 11 mo ago | 25 | Valerie Vanhooren Co-Founder & CEO | WordPressBugHerdMySQL+19 | 30 patents Targeted oncology therapeutics: FGFR4 inhibitors and CD36 antibody cancer treatments. | — |
| 3 | SOM Biotech Developer of platform for screening compounds to treat rare diseases | $29M | 33 mo ago | 15 | Raul Insa Founder & CEO | — | 117 patents Pharmaceutical compounds and formulations for treating dystrophinopathies, movement disorders, and PKU | — |
| 4 | ORYZON Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology… | $25M | 16 mo ago | 43 | Carlos Buesa CEO | DrupalApple iCloud MailMicrosoft 365+10 | — | — |
| 5 | Peptomyc Cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment | $23M | 5 mo ago | 18 | Marie-Eve Beaulieu Co-Founder | WordPressMySQLPHP+16 | 60 patents Oncologic combination therapeutics and biomarkers, plus immunomodulatory compounds for autoimmune disease | — |
| 6 | AbilityPharma Developer of drugs for the treatment of cancer diseases | $15M | 30 mo ago | 19 | Jordi Espadaler Co-Founder | Google MapsApache HTTP Serverlit-html+7 | — | — |
| 7 | Nuage Therapeutics Developer of drugs designed for intrinsically disordered targets | $13M | 39 mo ago | 15 | Judit Folgueira Co-Founder & CEO | WordPressMySQLPHP+21 | — | — |
| 8 | Mimark Developer of diagnostic solutions for treating patients with gynecological problems | $7M | 33 mo ago | 2 | Antonio Moreno Co-Founder & CMO | WordPressMySQLPHP+15 | — | — |
| 9 | Onechain Immunotherapeutics Developer of immunotherapies against hematological malignancies | $7M | 30 mo ago | 10 | Pablo Menendez Founder | RubyTrixYouTube+7 | 28 patents Patents concentrated in chemistry & materials | — |
| 10 | Inbiomotion Developer of biomarkers to predict bone metastasis in cancer patients | $5M | 67 mo ago | 10 | — | — | 80 patents c-MAF biomarker diagnostics and targeted therapies for breast and prostate cancer | — |
| 11 | Gyala Therapeutics Developer of cell therapies for the treatment of hematological malignancies | $4M | 7 mo ago | 5 | — | — | 9 patents CD84-targeted antibodies and CAR‑T cell immunotherapies for cancer treatment | — |
| 12 | Leukos Biotech Developer of drugs targeting leukemic stem cells | $4M | 65 mo ago | 4 | — | — | 55 patents Serotonin 1B receptor modulators for solid‑tumor therapy and apomorphine‑palmitic acid cocrystal drugs | — |
| 13 | Gate2Brain Developer of platform for the delivery of therapeutics across biological barriers | $3M | 37 mo ago | 10 | Esther Riambau Co-Founder | — | 14 patents Peptide-based water‑soluble drug carriers and BBB‑shuttle antibody modifications for cancer therapy | — |
| 14 | Aptadel Therapeutics Developer of RNA-based therapeutics to treat cancer | $3M | 5 mo ago | 7 | Oscar Tirado Co-Founder | — | 3 patents Aptamer-based therapeutics targeting EPHA2 receptor for cancer treatment. | — |
| 15 | Lykera biomed Monoclonal antibodies (MAbs) as therapy for solid tumors | $2M | 123 mo ago | 1 | Juan Ruiz CEO | — | 55 patents Antibody therapeutics and diagnostics targeting S100 family proteins for cancer and fibrosis. | — |
| 16 | Transbiomed Provider of genomics and proteomics based molecular diagnostics solutions | $2M | 187 mo ago | — | Andreas Doll Co-Founder | — | — | — |
| 17 | Oniria Therapeutics Developer of therapeutics for cancer treatment | $1M | 40 mo ago | 7 | Josep Tabernero Co-Founder | — | — | — |
| 18 | Nanobots Therapeutics Developer of therapeutics for the treatment of cancer | $509K | 21 mo ago | 6 | Andres Fernandez Co-Founder | Froala EditorVimeoBootstrap+14 | — | — |
| 19 | Pangaea Biotech Provider of drug development and molecular diagnostics services on cancer treatment | $298K | 104 mo ago | 55 | — | WordPressMySQLPHP+22 | 104 patents Molecular diagnostics and targeted oncology therapeutics using nucleic acids and luminescent assays | — |
| 20 | YSOTOPE Developer of radiotracers to monitor CAR-T cells inside the patient’s body | $160K | 38 mo ago | 5 | Carlos Gavilan Co-Founder & CEO | — | — | — |
| 21 | Xenopat Developing xenograft models of cancer for drug development and personalized treatment selection | $158K | 68 mo ago | 4 | Alberto Villanueva Co-Founder | — | — | — |
| 22 | MiWEndo Solutions Developer of electromagnetic endoscopy for colorectal cancer detection | $121K | 67 mo ago | 19 | Gloria Esparrach Co-Founder | WordPressMySQLPHP+22 | 2 patents Medical endoscopic accessories for diagnostic and therapeutic procedures | — |
| 23 | Moirai Biodesign Developer of RNA-based therapeutics and diagnostics for cancer | $115K | 87 mo ago | 6 | Ivan Dotu Co-founder and CTO | — | 11 patents RNA aptamer‑based signal amplification methods for nucleic‑acid disease diagnostics | — |
Top 12 Oncology companies in Catalonia
#1
Series C · Barcelona, Catalonia · founded 2014 · 18 employees$22.6Mraised▾
Peptomyc, a spin-off of the Vall d’Hebron Institute of Oncology (VHIO) is focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. Its lead peptide Omomyc-CPP is in the preclinical stage.
- Apr 2026Series C$5.8M
- Feb 2026Series B—
- Oct 2023Grant (prize money)$2.6M
- Oct 2023Series B$2.6M
#2
Series A · Barcelona, Catalonia · founded 2019 · 25 employees$35.5Mraised▾
Ona Therapeutics provides therapeutics solution for metastatic cancer. It is a spin-off of ICREA and IRB and involved in developing biologics targeting the metastatic-initiating cells and lipid metabolism for the treatment of cancer.
- Oct 2025Series A$11.6M
- Dec 2020Grant (prize money)—
- Jun 2020Series A$33.8M
- May 2019Seed$1.7M
#3
Seed · Barcelona, Catalonia · founded 2020 · 7 employees$2.8Mraised▾
Developer of RNA-based therapeutics to treat cancer. The company's technology is based on RNA-Aptamers to deliver different therapeutic agents to treat a wide variety of cancers. The company's lead candidate drug is ADEL-101 for Ewing Sarcoma, a rare variety of bone cancer in children and young adults.
- Mar 2026Seed$2.3M
- 2025Seed$498.5K
#4
Early Stage · Barcelona, Catalonia · founded 2020 · 5 employees$4.4Mraised▾
Developer of cell therapies for the treatment of hematological malignancies. The company is developing CAR T cell products against a novel target overexpressed in several hematological malignancies. The product line inlcudes ARI-0001 and ARI-0002 for chronic lymphocytic leukemia (CLL), Burkitt’s lymphoma, acute myeloid leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL).
- Feb 2026Grant (prize money)$4.4M
#5
Public · Barcelona, Catalonia · founded 2000 · 43 employees$24.9Mraised▾
Developer of treatments solutions for cancer and neurodegenerative diseases using epigenetic technology platforms. It uses a proprietary epigenetic platform to identify drug targets for cancer and neurodegenerative diseases. Its lead candidate targets lysine-specific demethylase - 1 (LSD-1) for Alzheimer's, Parkinson's, Huntington's, and certain other rare diseases.
- Apr 2025Post IPO$34.1M
- Sep 2021Grant (prize money)$1M
- Jul 2019Post IPO$22.3M
- Mar 2017Post IPO$19.5M
#6
Series B · Barcelona, Catalonia · founded 2009 · 15 employees$28.5Mraised▾
SOM Biotech is developing therapies for rare diseases. The company has developed a proprietary ligand-based in-silico platform for virtual compound screening. The company has developed a drug pipeline that includes SOM0226 for the treatment of TTR amyloidosis (phase II) and SOM3355 for the treatment of Huntington's disease (phase II). The other products in the pipeline include compounds for the treatments for cystic fibrosis, glioblastoma, and Alzheimer's disease.
- Dec 2023Series B$18.5M
- Mar 2019Series A$7.9M
- Jan 2017Seed$2.1M
#7
Series B · Barcelona, Catalonia · founded 2009 · 19 employees$14.5Mraised▾
Ability Pharma is a developer of drugs for the treatment of cancer diseases. It has developed the ABTL0812 product that indicated for solid tumors started phase I/Ib trials, first in humans in Feb.2014. They have 4 other molecules in preclinical and discovery validation stages such as ABTL0815, ABTL0814, and others.
- Mar 2024Series B$7.7M
- Jul 2020Grant (prize money)$2.6M
- Sep 2019Series A$3.9M
- Feb 2013Grant (prize money)$1.6M
#8
Seed · Barcelona, Catalonia · founded 2020 · 10 employees$7.3Mraised▾
Developer of immunotherapies against hematological malignancies. The company develops immunotherapies against hematological neoplasms using CAR-T candidates against different antigens. The product pipeline inlcudes OC-1 CART CD1a immunotherapy for refractory relapsed patients, OC-2 CART CD22 Immunotherapy, and OC-3 a T-cell allogeneic platform.
- Feb 2024Grant (prize money)$2.4M
- Jun 2023Seed$7.3M
- Apr 2023Grant (prize money)$1.6M
#9
Seed · Barcelona, Catalonia · founded 2021 · 2 employees$7.5Mraised▾
Developer of diagnostic solutions for treating patients with gynecological problems. The company is involved in the development of biomarkers that acts as an indicator of a particular disease state. It can be introduced into an organism to examine organ function or to evaluate abnormal vaginal bleeding problems in women. It also helps in the diagnosis of endometrial cancer.
- Nov 2023Seed$4.6M
- Jun 2023Seed$1.1M
- Feb 2021Seed$1.8M
#10
Seed · Barcelona, Catalonia · founded 2021 · 15 employees$13.1Mraised▾
Developer of drugs designed for intrinsically disordered targets. The company develops drug screening assays to target intrinsically disordered proteins that undergo biomolecular condensation and provide treatment of castration-resistant prostate cancer.
- Jun 2023Seed$13.1M
#11
Seed · Barcelona, Catalonia · founded 2023 · 6 employees$509.1Kraised▾
Developer of therapeutics for the treatment of cancer. It offers a lead candidate NBT-101 for bladder cancer, NBT-102 for colorectal cancer, and others. It offers a proprietary MotionTx technology platform to develop therapeutic candidates that cano cross biological barriers and accumulate in target cells.
- Dec 2024Seed$1.1M
- Sep 2023Seed$509.1K
#12
Series C · Barcelona, Catalonia · founded 2010$53.7Mraised▾
Provider of a diagnostic platform for molecular diagnostics and immunoassays. The proprietary DiagCore comprises an Analyzer that runs on consumable DiagCore cartridges. The STAT-Molecular cartridge automates sample homogenization, cell disruption, nucleic acid purification and delivers up to 50-plex target detection employing qPCR. This test cartridge is designed to automate molecular assays in the fields of infectious diseases, oncology, coagulation, prenatal, inherited diseases, or companion diagnostics. It offers test cartridges designed to automate immunoassays for critical care markers such as Procalcitonin (Sepsis), Troponin (AMI), Ngal (AKI), C-reactive protein (Inflammation), hCG (pregnancy), among others.
- Oct 2016Series C—
- Apr 2016Series C$28.5M
- May 2013Series B$22.3M
- 2011Series A$2.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Spain
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 933 Spain-affiliated papers.
- Centro de Investigación Biomédica en Red de Cáncer107
- Clinica Universidad de Navarra82
- Cancer Research Center60
- Instituto de Salud Carlos III55
- Universidad de Navarra49
- Tumor microenvironment4→118
- Immune system2→83
- Cancer research5→70
- Immunotherapy3→66
- Cancer immunotherapy3→31
- Tumor microenvironment7→193
- Immune system4→148
- Immunotherapy6→136
- Cancer research12→131
- Cancer immunotherapy6→62
- Tumor microenvironment5→57
- Immunotherapy6→58
- Immune system6→45
- Cancer immunotherapy3→28
- Cancer research3→18
Where oncology is researched across Spain
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.